All filters
Videos
World Bank and Pandemic Preparedness - Olusoji Adeyi, MD, DrPH, MBA
Presented at:
International Conference on (Re-) Emerging Infectious Diseases (ICREID) 2019
Videos
Reflecting on 100 Years of Pandemic Flu and Other Emerging Infections - David Heymann, MD, PhD
Presented at:
International Conference on (Re-) Emerging Infectious Diseases (ICREID) 2019
Slidesets
The African Centres for Diseases Control and Prevention- John Nkengasong, PhD, MSC
Presented at:
International Conference on (Re-) Emerging Infectious Diseases (ICREID) 2019
Slidesets
Rift Valley Fever - David Soti, MBChB, MPH
Presented at:
International Conference on (Re-) Emerging Infectious Diseases (ICREID) 2019
Slidesets
Risk Communication and Risk Perception in the 2014-2015 Ebola Outbreak in Sierra Leone - Maike Winters
Presented at:
International Conference on (Re-) Emerging Infectious Diseases (ICREID) 2019
Slidesets
Propagation of Drug Resistance by Clinicians Through Concurrent Treatment of Malaria and Typhoid Fever Among Patients Presenting with Febrile Illnesses in a Municipal Hospital in Ghana 2017 - Tanko Rufai
Presented at:
International Conference on (Re-) Emerging Infectious Diseases (ICREID) 2019
Slidesets
A Situation Analysis of Antibiotic Consumption and Its Potential Contribution to Antimicrobial Resistance in Nigeria - Abiodun Egwuenu
Presented at:
International Conference on (Re-) Emerging Infectious Diseases (ICREID) 2019
Slidesets
Lunch Symposium - challenges in EID preparedness, the Yellow fever case - Marion Koopmans, DVM, PhD
Presented at:
International Conference on (Re-) Emerging Infectious Diseases (ICREID) 2019
Slidesets
Development of protease inhibitors against norovirus and other emerging viruses | Ladislau Kovari
Presented at:
HIV DART and Emerging Viruses 2018
Videos
Zika and other emerging viruses in the Americas | Mehul Suthar
Presented at:
HIV DART and Emerging Viruses 2018
Slidesets
Abstract: A pharmacometric framework for dose individualisation of sunitinib in GIST (#O2) | Maddalena Centanni
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Rationale for selecting combinations with immunotherapy | Howard Gurney, MBBS, FRACP
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Immunotherapy of prostate cancer and urothelial cancer. Future directions | Winald Gerritsen, MD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Pharmacotherapy of Comorbities: Cancer Patients with HIV/AIDS | Michelle Rudek, PharmD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Drug-Drug interactions with targeted oncolytics (in particular PPIs and TKIs) | Ron Mathijssen, MD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Drug-drug interaction management with DDI-Predictor | Michel Tod, PharmD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Abstract: Food intervention to make therapy with pazopanib more patient friendly and affordable (#06) | Floor Lubberman
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
The value of surrogate endpoints in the benefit-risk assessment of new drugs | Gabe Sonke, MD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Abstract: Novel online drug-drug interaction resource reveals clinically relevant interactions in >20% of the searches (#05) | Stefanie Krens
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Abstract: A Pharmacokinetic-Pharmacodynamic binding model of Bevacizumab to VEGF as a tool to optimize treatment (#07) | Apostolos Papachristos
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Abstract: A generalisable pharmacokinetic-pharmacodynamic (PKPD) model of savolitinib, a novel MET tyrosine kinase inhibitor, to explore extent and duration of target inhibition required for optimal efficacy across a range of tumour xenograft models (#O8)
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
How studies can be optimized by simultaneous use of PK/PD outcome measurement? | Alwin Huitema, PharmD, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Clinical relevance of liquid biopsy in cancer patients | Catherine Alix-Panabières, PhD
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018
Slidesets
Abstract: Translation from mouse to human of pharmacokinetic-pharmacodynamic modelling of biomarker response – learnings from the AstraZeneca Oncology portfolio (#10) | Rhys Jones
Presented at:
International Workshop on Clinical Pharmacology of Anticancer Drugs (ICPAD) 2018